Crona Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Crona Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Jun 27, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Apr 25, 2023 |
| FY2020 | Dec 31, 2020 | $0 | Apr 1, 2021 |
| FY2020 | Dec 31, 2019 | $0 | Apr 1, 2021 |
| FY2018 | Dec 31, 2018 | $0 | Aug 11, 2020 |
| FY2018 | Dec 31, 2017 | $36.2K | Aug 11, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($77.4K) | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | ($193.6K) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $45.1K | Jun 27, 2024 |
| FY2022 | Dec 31, 2021 | ($17.6K) | Apr 25, 2023 |
| FY2021 | Dec 31, 2020 | $24.1K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.2K) | Apr 1, 2021 |
| FY2018 | Dec 31, 2018 | ($19.5K) | Aug 11, 2020 |
| FY2018 | Dec 31, 2017 | ($18.7K) | Aug 11, 2020 |
| FY2017 | Dec 31, 2016 | ($923) | Apr 18, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($77.4K) | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | ($193.6K) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $45.1K | Jun 27, 2024 |
| FY2022 | Dec 31, 2021 | ($17.6K) | Apr 25, 2023 |
| FY2021 | Dec 31, 2020 | $24.1K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.2K) | Apr 1, 2021 |
| FY2018 | Dec 31, 2018 | ($19.5K) | Aug 11, 2020 |
| FY2018 | Dec 31, 2017 | ($18.7K) | Aug 11, 2020 |
| FY2017 | Dec 31, 2016 | ($923) | Apr 18, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $24.0K | Apr 18, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($20.1K) | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | ($120.1K) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($43.9K) | Jun 27, 2024 |
| FY2022 | Dec 31, 2021 | ($1.1K) | Apr 25, 2023 |
| FY2020 | Dec 31, 2020 | ($36.4K) | Apr 1, 2021 |
| FY2020 | Dec 31, 2019 | $0 | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | ($9.4K) | Nov 3, 2020 |
| FY2018 | Dec 31, 2017 | ($19.7K) | Aug 11, 2020 |
| FY2017 | Dec 31, 2016 | ($2.5K) | Apr 18, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $39.1K | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $68.8K | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $102.5K | Jun 27, 2024 |
| FY2022 | Dec 31, 2021 | $22.0K | Apr 25, 2023 |
| FY2021 | Dec 31, 2020 | $8.9K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Nov 3, 2020 |
| FY2018 | Dec 31, 2017 | $26.2K | Aug 11, 2020 |
| FY2017 | Dec 31, 2016 | $6.7K | Apr 18, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $308.6K | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $260.9K | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $101.8K | Jun 27, 2024 |
| FY2022 | Dec 31, 2021 | $66.5K | Apr 25, 2023 |
| FY2021 | Dec 31, 2020 | $35.7K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.8K) | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | ($1.6K) | Nov 3, 2020 |
| FY2018 | Dec 31, 2017 | $17.9K | Aug 11, 2020 |
| FY2017 | Dec 31, 2016 | $2.6K | Apr 18, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($269.5K) | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | ($192.1K) | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | $690 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($44.5K) | Jun 27, 2024 |
| FY2022 | Dec 31, 2020 | ($26.9K) | Apr 25, 2023 |
| FY2021 | Dec 31, 2019 | ($2.8K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | ($1.6K) | Apr 1, 2021 |
| FY2018 | Dec 31, 2017 | $17.9K | Aug 11, 2020 |
| FY2018 | Dec 31, 2016 | $4.1K | Aug 11, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($307.8K) | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | ($230.4K) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($36.8K) | Jun 27, 2024 |
| FY2022 | Dec 31, 2021 | ($81.9K) | Apr 25, 2023 |
| FY2021 | Dec 31, 2020 | $64.4K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($40.3K) | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | ($39.1K) | Nov 3, 2020 |
| FY2018 | Dec 31, 2017 | ($19.6K) | Aug 11, 2020 |
| FY2017 | Dec 31, 2016 | ($923) | Apr 18, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $0 | Aug 11, 2020 |
| FY2018 | Dec 31, 2017 | $31 | Aug 11, 2020 |
| FY2017 | Dec 31, 2016 | $214 | Apr 18, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Feb 27, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 6.59M | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | 6.59M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 6.09M | Jun 27, 2024 |
| FY2022 | Dec 31, 2021 | 6.09M | Apr 25, 2023 |
| FY2021 | Dec 31, 2020 | 6.09M | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | 6.09M | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | 6.09M | Nov 3, 2020 |
| FY2018 | Dec 31, 2017 | 6.09M | Aug 11, 2020 |
| FY2017 | Dec 31, 2016 | 5.00M | Apr 18, 2018 |